Easy Find It Page
Easy Find It
Use Our Mobile Site
Use Our Mobile Site
Share This Website
The Sugar Trehalose
Free NEWS Letter
Affiliate Program
Untitled Document

Already an Affiliate? Click on the link below to access your account-

Affiliate Login

Endowment Book Store
The Trehalose Store
Endowment Store Front
Support The Endowment
Enter Amount:
We Accept
VisaMaster CardAmerican ExpressDiscoverssl lock
Download Store

Download Store

Download 7 Free Newsletters Plus Other Educational Materials

Main Menu
Home
- - - - - - -
Inside the Human Cell
The Sugar Trehalose
- - - - - - -
Sugar Science Forum
Glycomics Training
Interactive Glycomics Brochure
NEWS
7 FREE NEWSletters
HOT Links of Interest
- - - - - - -
Contact Us
Disclaimer
Sitemap
Educational e-textbook
Chapter One

Chapter One

FREE Sneek Peek
Chapter One


Evaluation Forms

Huntington’s General
Health Evaluation
FORM for Trehalose
Nutritional Pilot Survey

Parkinson's General
Health Evaluation
FORM for Trehalose
Nutritional Pilot Survey

Alzheimer / Dementia
General Health Evaluation
FORM for Trehalose
Nutritional Pilot Survey

Diabetic Health Evaluation
FORM for Trehalose
Nutritional Pilot Survey

General Public Health
Evaluation FORM for
Trehalose Nutritional
Pilot Survey (For General
Public without Huntington’s,
Alzheimer’s, or Parkinson’s.)

Who's Online
We have 141 guests online
Toxic RNA Contributes to Neurodegeneration

Commentary by J. C. Spencer

Mitochondria micrograph source: University of Texas Medical Branch (UTMB)
Mitochondria micrograph source: University of Texas Medical Branch (UTMB)
Researchers in neurodegenerative diseases at Howard Hughes Medical Institute have linked toxic RNA with Huntington’s disease. This significant discovery reveals the importance for improving the function of the mitochondria where the RNA is manufactured as well as correcting the altered gene expression that causes Huntington’s. After reading this report, connect the dots to the published Huntington’s paper entitled, Trehalose alleviates polyglutamine-mediated pathology in mouse model of Huntington disease. Please understand, these two papers are dealing with mice and fruitflies. Further research is needed in the human population with Huntington’s. This new information may give us an indication as to why we are having positive results in those participating in our self funding, self evaluation Trehalose Nutritional Pilot Survey. All that is required to participate in this Huntington study is for the individual or family to complete a self evaluation form each month while using trehalose over time. The longer a Huntington’s patient is in the study the more data can be gathered. The Forms can be downloaded from the Home Page at www.endowmentmed.org

In studies with fruitflies, researchers have discovered that a mutant RNA may be partially to blame for the neurodegeneration associated with spinocerebellar ataxia type 3 (SCA3). The toxic RNA may exacerbate the disease, which causes loss of muscle coordination and paralysis of the eye muscles and is known to be caused by the buildup of an aberrant protein inside neurons.

The scientists said their findings suggest that treatments that target the abnormal RNA might offer double benefits by alleviating both the protein as well as RNA toxicity.

“One possibility our findings suggest is that treatments that seek to alleviate Huntington’s and other polyglutamine diseases by knocking down the RNA could offer two-pronged benefits.”
Nancy M. Bonini

Howard Hughes Medical Institute investigator Nancy M. Bonini and her colleagues published their findings April 30, 2008, in an advance online publication in the journal Nature. Co-authors include Lin-Bo Li, Zhenming Yu and Xiuyin Teng, who were all members of Bonini's laboratory at the University of Pennsylvania.

Over the last decade, Bonini and her colleagues have painstakingly recreated models of human neurodegenerative disease in the fruit fly. Their work involves introducing the gene for the human neurodegenerative disease into the fly, recreating the effects of the disease so that it can be studied in a highly manipulable system.

In the studies reported in Nature, the researchers used a strain of the fruitfly Drosophila that had a mutation in the gene that is altered in human patients with SCA3. This fruitfly strain exhibits neural degeneration and is a useful laboratory model for human SCA3.

SCA3 is one of a class of diseases known as polyglutamine repeat diseases. SCA3 and the other polyglutamine diseases, like Huntington's disease and SCA1, are caused by genetic mutations consisting of an abnormally long number of repeats of three nucleotides, also known as triplet repeats. The length of the “genetic stutter” of nucleotides can vary in each disease. For this set of diseases, the repeated nucleotide triplet is CAG, which encodes an amino acid called glutamine. The mutant version associated with human disease thus leads to a protein with an abnormally long glutamine string. The malformed protein is toxic to cells and causes neurological degeneration.

In SCA3 and similar diseases, the length of this glutamine string can grow as it is passed down from one generation to the next. This feature of the disease, called repeat instability, has important clinical implications because expansion of repeats causes the disease to arise earlier and with greater severity in successive generations of people who carry the mutation, Bonini explained.

When the genetic causes of polyglutamine diseases were first identified, researchers found that the aberrant proteins were toxic, but they did not look closely at whether the RNA could be toxic as well, Bonini said. To convert a gene into protein, cells begin by copying DNA into RNA. The RNA molecule serves as the template the cell uses to build a protein.

Bonini and her colleagues did not set out to use their fruitfly model of SCA3 to search for signs of RNA toxicity. Rather, they let the fly tell them in an unbiased way about genes that could improve or worsen symptoms of the disease. During these studies, the researchers discovered that activating the muscleblind (mbl) gene in the flies dramatically increased neural degeneration.

Further analyses suggested that the mbl gene exacerbated the disease by interacting with RNA. And when the researchers inserted the human version of the mbl gene into the fly, they saw that the neurodegeneration also worsened, providing a hint that mbl might also play a role in human polyglutamine diseases.

Intrigued by the possibility that the RNA itself was toxic, Bonini and her colleagues next molecularly interrupted the repetitive RNA sequence. Normally, the RNA has a long series of CAG repeats; the researchers interrupted the sequence so that it now had CAA and CAG repeats This RNA sequence encodes the same mutant protein, but the RNA was not predicted to fold in the same toxic manner. When they introduced this interrupted RNA back into their fruitflies, significantly less neurodegeneration occurred, further indicating that the RNA itself might be toxic.

Then the researchers genetically engineered mutant flies that produced only the repetitive RNA but no aberrant protein. Those flies showed significant neural degeneration. “That finding suggested that the RNA on its own contributes to the pathology,” said Bonini.

She said the new results reveal that polyglutamine diseases like SCA3 and Huntington's disease may share the property of RNA toxicity with a different class of triplet repeat diseases, which includes myotonic dystrophy type 1 and fragile X-associated ataxia. Those diseases also arise from genetic mutations that produce a stuttering RNA. That RNA does not, however, produce an abnormal, toxic protein; the pathology of those diseases is thought to arise only from the toxicity of the RNA.

Although the new studies suggest that the two classes of triplet repeat diseases are caused in part by RNA toxicity, Bonini said their analyses indicate that the mechanism of RNA toxicity appears to be different for each class of disease. In future studies, the researchers will concentrate on determining the mechanisms of RNA toxicity in the polyglutamine disease fly model, she said.

Bonini said the new findings could offer the promise of more effective treatments for polyglutamine diseases. “One possibility our findings suggest is that treatments that seek to alleviate Huntington's and other polyglutamine diseases by knocking down the RNA could offer two-pronged benefits,” she said. “They would not only reduce the level of the toxic protein, but also knock down the toxic RNA. Thus, such treatments might be more effective than those directed only at the protein,” she said.

Ling-Bo Li is now a postdoc in a Hughes Lab at Utah (with Brenda Bass).

Last Updated ( Jul 21, 2008 at 09:26 AM )